Compare Nomura Holdings Inc (NMR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Nomura Holdings Inc trades at $9.4 (market cap $27.46B), while Regeneron Pharmaceuticals Inc trades at $670 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.6× Nomura Holdings Inc's market cap, and Nomura Holdings Inc pays the higher dividend (3.45%). Which is the better fit depends on your goals.
| NMR | REGN | |
|---|---|---|
Market Cap | $27.46B | $70.47B |
Sector | Financials | Health |
52-Week High | $10.04 | $812.27 |
52-Week Low | $6.39 | $545.46 |
Dividend Yield | 3.45% | 0.56% |
Enterprise Value | — | $64.42B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
